BRAF wild-type

We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy...In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.

The minimally invasive anatomical approach allowed precise vascular control and achievement of oncologically adequate margins in a technically demanding central segment. Larger clinical series are needed to define optimal management strategies and long-term oncologic outcomes in this setting.

Increasing age at the time of first-line therapy for advanced disease stage was associated with a statistically significant increase in the hazard of death (p = 0.031). In the advanced disease stage, RAS/BRAF wild-type colorectal cancers were significantly associated with a survival advantage.

This pooled analysis of candidates considered optimal for initial anti-EGFR-based therapy supports both stop and go and maintenance as de-intensification strategies to consider in shared decision making. Adequately powered phase III studies are advocated to compare the two strategies.

BRAFV600E and TERT promoter co-mutation, identifiable preoperatively, defines a distinct PTC subtype with a profoundly aggressive clinicopathological profile and a significantly elevated risk of recurrence. This combined molecular signature is a potent preoperative biomarker for stratifying patients into the highest-risk category, potentially guiding more individualized initial therapeutic strategies.

Epinephrine or glial cell line-derived neurotrophic factor also stimulated migration specifically in BRAF-mutated cells. These results emphasize the importance of targeting specific neural signaling pathways and highlight that patient stratification is essential for cancer neuroscience studies.

P2, N=10, Not yet recruiting, Haihua Yuan

NF1 mutation is the strongest gene-level correlate of lung-selective metastasis in cutaneous melanoma. The NF1-mutant subtype may represent a dual-biomarker population and could warrant both pulmonary surveillance and prospective evaluation for immunotherapy.

Current evidence supports DNA methylation as a promising refinement biomarker, but not yet as a stand-alone decision tool. Prospective validation, assay standardization, and integration with ctDNA-guided resistance assessment are required before routine implementation.

P2, N=216, Completed, Melanoma Institute Australia | Trial completion date: Dec 2025 --> Mar 2026

P1, N=10, Not yet recruiting, West China Hospital

P=N/A, N=70, Not yet recruiting, Niguarda Hospital